NeuroPace, Inc.

As of June 3, 2021, NeuroPace, Inc. is considered a risky investment due to its high valuation metrics and underperformance relative to peers, despite a 51.32% return over the past year, significantly outperforming the S&P 500's 17.14%.

As of June 3, 2021, NeuroPace, Inc. is considered overvalued and risky due to significant negative financial ratios, including a Price to Book Value of 17.77 and a Return on Equity of -102.91%, alongside poor stock performance compared to the S&P 500.

As of June 11, 2025, the market trend is mildly bullish, supported by daily moving averages, but tempered by mixed signals from weekly indicators and caution from MACD and Bollinger Bands.

NeuroPace, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $23 million and a net loss of $7 million as of March 2025. Key financial metrics include a market cap of $353.57 million, a P/E ratio of NA, and a dividend yield of 0.00%.

As of Jun 18, NeuroPace, Inc. has a market capitalization of 353.57 million, with net sales of 84.31 million and a net profit of -24.80 million over the last four quarters. The company reported shareholder's funds of 8.01 million and total assets of 94.65 million as of Dec 24.